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ABSTRACT 
Objective: The purpose of the present investigation was to develop and optimize nitrendipine loaded niosomal gel for transdermal delivery using 
quality by design approach.  
Methods: Niosomal formulations were developed by application of the thin-film hydration method using different ratios of span 60, cholesterol, 
temperature, and optimized by three factors-three levels Box-Behnken statistical design. The independent variables were non-ionic surfactant, 
cholesterol, and temperature, while vesicle size, polydispersity index, and entrapment efficiency were dependent variables. The nitrendipine loaded 
optimized formulation was incorporated into gel and evaluated for in vitro release, ex-vivo skin permeation, confocal laser scanning microscopy, and 
histopathological studies.  
Results: The optimized formulation showed the vesicular size of 226.1±4.36 nm, polydispersity index of 0.282±0.012, and entrapment efficiency of 
95.34±3.18% with spherical morphology. The optimized niosomal gel formulation showed transdermal flux 127.60 µg/cm2h through albino Wistar 
rat skin. Niosomal gel was proved significantly superior by confocal laser scanning microscopy for satisfactory permeation and distribution of gel, 
deep into the rat skin. Furthermore, dermal safety was confirmed by histopathological studies for transdermal application.  
Conclusion: It was concluded that the developed niosomal gel overcomes the limitation of low penetration through rat skin and could be a potential 
nano vesicular system for transdermal delivery.  
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INTRODUCTION 
Hypertension is a chronic condition responsible for a cardiovascular 
event and is ranked the third most important cause of public health 
issues in developed countries [1, 2]. Globally, more than one billion 
adults, and by 2025, 1.5 billion populations are estimated to get 
effected by uncontrolled hypertension [3]. Genetic and synergistic 
factors like stress, tobacco, alcohol intake, sedentary lifestyle, 
smoking, and obesity play a remarkable role in hypertension [4]. 
Various classes of drug and treatment have been advocated for the 
control of hypertension, due to its incidence and morbidity. 
Treatment with antihypertensive agents decreases cardiovascular 
events such as heart attack, heart failure, and stroke [5, 6]. In the 
past decades, calcium channel blockers have been well established 
in the management of coronary heart disease by inhibiting calcium 
ion entry into a cardiac and vascular smooth muscle to promote 
vasodilatation [7, 8].  
Nitrendipine (3-ethyl-5-methyl-1, 4-dihydro-2,6-dimethyl-4-(3-
nitrophenyl)3,5-pyridine dicarboxylate) a calcium channel antagonist, 
is used to treat the patients with mild or persistent hypertension [9, 
10]. Nitrendipine is given with oral doses of 5-20 mg/day and 
classified as BCS (biopharmaceutical classification system) class II 
drug with high lipophilicity. Its systemic bioavailability is low and 
erratic i.e. 10-20% due to extensive first-pass metabolism after oral 
administration. It was stated that dissolution is a rate-limiting step 
that results in inter-subject pharmacokinetic variability while taken 
orally. Nitrendipine appears to have different effects on calcium ion 
kinetics than that of conventional calcium antagonists without 
negative ionotropic effects and it does not affect impulse conduction 
and generation [11, 12]. 
In this context, numerous novel approaches have already been 
explored by formulating a transdermal patch [13] and 
nanoformulations [14-17] with a limited outcome. All these above 
formulations enhanced bioavailability and solubility of the class-II 
drug but reported drug expulsion during storage with less loading 
capacity. Despite using the approaches stated above, the use of 
niosome as nanocarrier offers several advantages like; improved 
pharmacokinetics and biodistribution, depot to release the drug 
slowly, increased therapeutic potential by retaining to the target 
site, deep penetration in stratum corneum by acting as a penetration 
enhancer and greater stability [18, 19]. Niosomes are structurally 
similar to liposome, but low cost and greater stability of surfactant 
make them an ideal alternate over liposome. Recently, there has 
been growing interest in the vesicular systems with bilayer 
membranes for potential drug delivery. Niosomes are composed by 
self-association of non-ionic surfactant and cholesterol in the 
aqueous phase. Niosomes show an effective novel drug delivery due 
to its unique structure, high stability, long shelf-life, and capacity to 
encapsulate lipophilic and hydrophilic drugs. The niosomes are 
biodegradable, non-immunogenic, biocompatible, and magnificent 
polymeric vesicle that shows a wide range in the sustained and 
targeted delivery [20, 21]. The stratum corneum is the outermost 
layer of the skin, which acts as the greatest obstacle in the crossing 
of drug and vaccine due to its anatomical peculiarities [22]. The 
vesicle’s interaction with stratum corneum leads to adherence, 
aggregation, and fusion by creating the driving force for the 
penetration of lipophilic drugs [23]. The low oral bioavailability, low 
dose, low molecular weight (360.4), extensive first-pass effect, 
lipophilic nature (octanol/water partition coefficient 2.88) indicates 
that nitrendipine might be a good choice as a drug candidate for 
transdermal delivery [15]. By using three-factor three-level Box-
Behnken statistical design, no specific research report available, 
hence in the present investigation, niosomal gel for transdermal 
delivery was prepared and evaluated.  
The primary objectives of the present investigation were to (a) 
explore the feasibility of niosome as a carrier for transdermal 
delivery (b) optimization by using three-factor three-level Box 
Behnken statistical design (c) determine the size, polydispersity 
index (PDI) and entrapment efficiency (EE) (d) investigate deep 
penetration into the rat skin by confocal laser scanning microscopy 
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(CLSM) (e) perform ex-vivo permeation through rat skin (f) ensure 
safety for dermal application by histopathological studies.  
MATERIALS AND METHODS 
Materials 
The following materials were procured from the indicated sources 
devoid of any further purification. Nitrendipine was purchased from 
Wuhan Jing Chu Chen Pharmaceutical, Chemical Co Ltd, China. Span 
60 was purchased from Sigma-Aldrich-S7010 MSDS and cholesterol 
was supplied by Loba chemicals. Carbopol 934P was obtained from 
Lubrizol Life Sciences and Triethanolamine was purchased from 
Fisher Scientifics. All other chemicals and reagents used were 
analytical grade.  
Animals 
The animals used were male albino Wistar rats (body weight 180-
250 g) obtained from central animal facility NIPER, Mohali. The 
animal experiment protocol was evaluated and approved by the 
Committee for the purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Government of India, and 
Institutional Animal Ethics Committee (IAEC), L. R Institute of 
Pharmacy, Solan (LRIP/IAEC/2018/PH-2). Rats were housed in 
polypropylene cages three per cage and nourished with a standard 
rat chow diet and water ad libitum. Animals were kept at 
temperature 25±2 °C and relative humidity (55±5%) with 12 h 
light/dark cycle by following the guidelines of laboratory animal 
care.  
Methods 
Preparation and optimization of niosome 
The niosomal formulations were prepared by the thin-film 
hydration method and optimized by box-behnken statistical design. 
The sorbitan esters have gained much attention; therefore, the most 
commonly used non-ionic surfactants (NIS) in the niosomal 
formulations. In the present research span 60 was selected as one of 
the NIS of choice for the preparation of vesicles [24]. The inclusion 
of cholesterol offers an increase in hydrodynamic diameter and thus 
leads to greater stability of surfactant by promoting gel liquid 
transition temperature of vesicle [18, 25]. Briefly, in 250 ml round 
bottom flask cholesterol, span 60 and nitrendipine were dissolved in 
diethyl ether. The organic solvent was then evaporated under 
reduced pressure by rotatory flash evaporator until dry, thin, and 
uniform film obtained. The thin lipid film thus deposited was 
hydrated with phosphate-buffered saline (pH-7.4) at room 
temperature to get niosomal dispersion. Further, the dispersion was 
sonicated using a probe sonicator (PKS 750F, PCi Analytica), four 
cycles of 30 s to convert multilamellar vesicles into desired size 
unilamellar vesicle [26, 27].  
Experimental design 
The optimization of the prepared formulations was done by using 3-
factor 3-level box-behnken statistical design (BBD) using Design 
Expert 11 (32-bit) software (Stat-Ease Inc., Minneapolis, USA). The 
design of the experiment is a technique developed to evaluate 
potential factors simultaneously, systematically, and speedily. The 
BBD is based on three-level incomplete factorial design and belongs 
to the class of rotatable or nearly rotatable second-order design [28, 
29]. It provides modeling of the response surface by assessing the 
risk and critical process parameters. This design is mostly used 
because it requires a comparatively small number of runs then 
compares to central composite design in the case of three 
independent variables. The design was used to employ the effect of 
independent variables on dependent variables. The design showed 
seventeen experimental runs, for which the software-generated 
quadratic equation is termed as:  
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In which, Y is the measured response related to dependable 
variables; β0 is constant; β1, β2, β3 are linear coefficients, β12, β13, β23 
are interaction coefficients among three factors whereas β11, β22, β33 
represent the quadratic coefficient. In this, A, B, and C are 
independent variables [27, 30], and the concentration range of the 
independent variables along with their different levels is listed in 
table 1. 
  
Table 1: Detail on the variables used for the preparation of nitrendipine niosomes by box-behnken design 
Factors Levels 
Independent variables Low Medium High 
A = Span 60 (mM) 3 4 5 
B = Cholesterol (mM) 1 3 5 
C = Temperature ( °C) 40 50 60 
Dependent Variables Goals 
Y1 = Vesicle size Minimize 
Y2 = Entrapment efficiency Maximize 
Y3 = Polydispersity index  Minimize 
 
The selected independent variables to carry out the experimental 
study were span 60 (A), cholesterol (B), and temperature (C), 
whereas vesicle sizes (Y1), entrapment efficiency (Y2), and 
polydispersity index (Y3) were dependable variables. The responses 
were evaluated using Analysis of variance (ANOVA) and linear 
regression by comparing the actual value with the predicted value. 
3-D response surface graphs and contour plots were generated 
using design expert software to assess the effect of an independent 
variable on the dependent variable. The optimized formulation was 
selected based on vesicle size, entrapment efficiency, polydispersity 
index, and converted to gel for further studies [27, 31].  
Characterization of optimized nitrendipine niosomes 
Vesicle size and polydispersity index  
The vesicular size and polydispersity index of nitrendipine loaded 
niosomes were determined by photon correlation spectroscopy, 
using Zetasizer (Malvern version 7.11 at 25 °C instrument U. K), 
which is based on the principle of dynamic light scattering (DLS) 
method [31, 32]. PDI was used to determine the width of size 
distribution and the value of PDI less than 0.4 indicates the 
homogenous and a monodisperse population [33, 34].  
Entrapment efficiency  
The entrapment efficiency of nitrendipine loaded niosomal 
formulation was estimated by the cooling centrifugation method. The 
prepared niosomal dispersion was poured into the stopper tube and 
centrifuged at 10,000 rpm at 4 °C for 90 min and followed by filtration 
to get a clear fraction. The free drug concentration in the supernatant 
was assayed by UV spectrophotometer. The percent drug entrapped 
was calculated by using the following equation [35, 45] 
EE(%) = [ (Total drug − unentrapped drug) ⁄ (Total drug) ] × 100  
Morphology of nitrendipine loaded niosomes 
The morphological characteristics of the prepared vesicles were 
examined by using transmission electron microscopy (Philips CM-
10, USA). The concentration of vesicles was reduced by diluting it 
with fivefold bidistilled water. One drop of the sample was pulled on 
to the carbon-coated copper grid and was negatively stained with 
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1% phosphotungstic acid before allowing it to dry as a thin film. 
Further, a piece of filter paper was placed to remove an excess of 
dispersion; the sample was air-dried and examined under the 
microscope to obtain images [33]. 
Preparation of nitrendipine niosomal gel  
The insufficient viscosity and inadequate retention of niosomal 
dispersion on the skin for a prolonged period of time, niosomal 
dispersion was converted into the gel. The optimized formulation of 
the niosome was selected based on vesicle size, entrapment 
efficiency, and polydispersity index. A gel base was prepared by 
adding 1 % w/w carbopol 934 P in distilled water with continuous 
stirring and was kept overnight for complete humectation of the 
polymer chain. Nitrendipine loaded niosomal dispersion equivalent 
to 10 mg was added with continuous stirring to carbopol solution 
for complete hydration. Triethanolamine (TEA) was added dropwise 
under gentle stirring with a glass rod to get the desired pH [36]. 
Rhodamine loaded niosomal gel was prepared similarly as 
mentioned above for confocal laser scanning microscopy.  
Evaluation of nitrendipine niosomal gel 
Physical appearance 
The prepared gel formulation was inspected for clarity, consistency, 
and homogeneity by visual inspection and also examined for the 
occurrence of any clumps or aggregates. 
Measurement of pH and viscosity 
This study was carried out to guarantee that the pH of developed 
niosomal gel is near to human skin pH. The pH of the optimized gel 
formulation was measured by using digital pH meter (Esico.1012, 
Potent Water Care, Pvt. Ltd) at room temperature by bringing into 
contact with the prepared gel for 1 min and allows pH value to 
stabilize [24]. The viscosity of nitrendipine niosomal gel was 
determined by using a digital Acutek A220B viscometer with an RH3 
spindle at 25±2 °C. The values were measured in triplicate to obtain 
a mean value. 
Drug content 
The nitrendipine loaded formulations were subjected to assay by 
analyzing it in a UV spectrophotometer. The drug content was 
quantified by dispersing 1 g gel in 25 ml of methanol and centrifuged 
at 15000 rpm at 4 °C for 30 min. The analysis was done in triplicate 
and the percentage drug content was calculated [37]. 
In vitro drug release 
In vitro drug release study was performed to select the best 
formulation for ex-vivo permeation by employing the paddle 
method using pH 7.4 phosphate buffer to mimic skin condition. A 
dialysis membrane was washed and soaked in distilled water to 
ensure complete swelling for providing constant pore diameter 
during the experiment. The vessel was filled with 500 ml phosphate 
buffer pH 7.4 and a speed of 50 rpm and a temperature of 32±1 °C 
was maintained throughout the experiment [27]. The niosomal gel 
equivalent to 10 mg of nitrendipine was placed on the dialysis 
membrane (molecular weight cut off 12000 Da) and was immersed 
at bottom of USP dissolution tester (Frontline electronics, 
Ahmedabad, India). Further, an aliquot of 1 ml from the receptor 
medium was withdrawn at different time intervals (0.5, 1, 2, 3, 4, 6, 
8, 10, 12, and 24 h) and immediately replaced with an equal quantity 
of fresh buffer solution to maintain sink condition [35]. The samples 
were analyzed for drug content by the U. V spectrophotometer and 
the amount of drug release was calculated as a function of time. The 
goodness of fit for zero-order, first-order model [38], Higuchi’s 
matrix model [39], and Korsmeyer-Peppas [40] was evaluated for 
drug release. For each model, the correlation coefficient (R2) was 
measured and the model giving value near to 1 was selected as the 
best fit model for drug release. 
Ex-vivo permeation study 
Male albino Wistar rats weighing 180-250 g were sacrificed and the 
fatty layer adhering to dermis was removed carefully by surgical 
scalpel [41]. Skin permeation of nitrendipine from niosomal gel 
formulation was studied by vertical type Franz cell (Orchid Scientific, 
J-FDC-07). The excised rat skin with proper dimension was mounted 
between two compartments of diffusion cell with the stratum 
corneum facing the donor compartment and dermis towards the 
receiver cell. The temperature of the receptor compartment 
(Phosphate buffer pH 7.4) was maintained at 37±1 °C and agitated 
with a small magnetic bead at 100 rpm [42]. An amount of niosomal 
dispersion, niosomal gel, and plain gel equivalent to 10 mg of the drug 
was placed in a donor cell and covered with aluminum foil to provide 
the occlusive condition. At different time intervals (0.5, 1, 2, 3, 4, 6, 8, 
10, 12, 24 h) 1 ml of aliquot was withdrawn and analyzed by U. V 
Spectrophotometer and every time receptor compartment was 
replenished with the same amount of fresh buffer.  
Permeation data analysis 
The amount of drug permeated through the rat skin (Q, µg/cm2) was 
plotted as a function of time for developed niosomal gel. The flux at 
steady state (Jss, µg/cm2 h) was calculated from the slope of the 
linear portion by plotting the amount of drug permeated per unit 
area of skin versus time [43]. 
Confocal laser scanning microscopy (CLSM) 
CLSM offers several advantages over light optical microscopy by 
providing three-dimensional images from thick rat skin [44]. It is 
used to examine the fluorescence signal of the optimized batch at 
different skin depths. The optimized niosomal formulation loaded 
with Rhodamine red (0.03%) and Rhodamine red solution (5 
mg/ml) was applied to the dorsal skin of albino Wistar rat 
homogeneously and non-occlusively. The experiment was done in 
the same manner as mentioned under ex-vivo permeation studies. 
After 8 h, excised rat skin was washed with distilled water, sliced 
into the small pieces, and was mounted on the slide with stratum 
corneum facing CLS microscope upward. The CLSM (Olympus, FV-
1000) studies were inspected by an argon laser beam with 
excitation at 488 nm and emission at 590 nm [27, 31].  
Skin irritation and histopathological studies 
The skin irritation test for optimized niosomal gel was performed 
using male albino Wistar rats. On the dorsal side, hairs of rat skin 
were removed 24 h before this portion of the experiment by electric 
clipper and were divided into three groups. The group I served as 
normal control (without treatment), group II treated with niosomal 
dispersion, niosomal gel was applied to group III [48, 46]. After 24 h, 
the application site was investigated for dermal reaction and graded 
zero to four using a visual scoring scale. The irritancy index was 
calculated as a sum of edema and erythema score for each group. 
Optimized formulation considered safe for dermal application if the 
irritation score is less than 2, irritant 2-5, and severely irritant when 
observed between 5 to 8 [24]. Further, histopathological studies 
were carried out on skins after sacrificing Wistar rats. The skin was 
separated, stored in 10 percent formalin until used for studies. The 
skin samples were dehydrated with ethanol stained with 
hematoxylin and eosin and investigated for any variation in rat skin 
under a light microscope and compared [27].  
Stability studies 
Stability studies for optimized niosomal gel were performed to 
determine any physical or chemical changes when subjected to different 
temperature i.e. 40±2 °C/75±5 % and 25±2 °C/60±5% relative humidity 
(RH). Periodically samples were withdrawn and analyzed for clarity, pH, 
and drug content at an interval of 1 or 2 mo [47, 49].  
Statistical analysis 
The optimized niosomal gel was analyzed by applying 1-way ANOVA 
followed by Tukey’s multiple comparisons test and accomplished 
using GraphPad Prism 6 software. All experiments were performed 
in triplicate and results were confirmed to be significant with a p-
value less than 0.05 (p<0.05) [26]. 
RESULTS AND DISCUSSION 
Fitting of experimental data to model 
A three-factor three-level Box-Behnken statistical design was 
employed and all individual and interactive effects of independent 
variables were examined. Niosomes were optimized by 
a second-order polynomial equation with quadratic responses for 
dependent variables. The responses were analyzed based on 
sequential model sum of squares, lack of fit, 
statistics. Probe more than the F-value of P<0.0001
residual error, low standard deviation, and
suggested a quadratic model for responses. A series of
  
Table 2: Detail on the observed response inbox
 Run Independent variables 
A (Span 60) B (Cholesterol) 
 NIF1 4.00 (0) 3.00 (0) 
NIF2 3.00(-1) 3.00 (0) 
NIF3 4.00 (0) 3.00 (0) 
NIF4 4.00 (0) 1.00 (-1) 
NI F5 5.00(+1) 1.00 (-1) 
 NIF6 5.00(+1) 3.00 (0) 
 NIF7 3.00(-1) 3.00 (0) 
 NIF8 4.00 (0) 5.00(+1) 
 NIF9 4.00 (0) 3.00 (0) 
 NIF10 5.00(+1) 5.00(+1) 
 NIF11 3.00 (-1) 1.00 (-1) 
 NIF12 3.00 (-1) 5.00(+1) 
 NIF13 4.00 (0) 3.00 (0) 
 NIF14 4.00 (0) 3.00 (0) 
 NIF15 4.00 (0) 5.00(+1) 
 NIF16 4.00 (0) 1.00 (-1) 
 NIF17 5.00(+1) 3.00 (0) 
 Opt-F 4.52 1.85 
 Data from each response is presented in mean±
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Dependent variables 
C (Temperature) Y1 (Vesicle size) (nm) Y2 (EE) (%)
50 (0) 345.5±5.71 85.15±1.89
40 (-1) 556.2±3.92 84.69±1.33
50 (0) 360.1±8.20 87.38±2.76
40(-1) 566.2±4.07 80.97±1.23
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50 (0) 366.0±7.48 85.52±1.30
50 (0) 334.2±4.69 80.04±3.46
50 (0) 325.1±6.51 80.04±2.33
40 (-1) 565.7±6.16 86.04±4.12
60 (+1) 235.6±7.12 95.97±2.12
40 (-1) 488.6±5.90 87.37±1.11
60 226.1±4.36 95.34±3.18
SD (n = 3) 
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Response 1 (Y1): effect of the independent variable on vesicle size
Vesicle size of niosomal formulation is an important criterion in 
transdermal drug delivery. The model F-value of 37.14 indicates the 
model was significant with only a 0.01 % chance that a “model F
value” this large could occur due to noise. The value of “Probe>F” 
less than 0.0500 implies model terms were significant and in this 
case, C, AB, C2were significant model terms. Values greater than 
0.1000 revealed the model terms were not significant. The “Lack of 
Fit F-value” of 4.10 pointed the lack of Fit was not significant relative 
to the pure error with only a 10.31 % chance that th
occur due to noise. The “predicted R-squared” of 0.7444 was in 
reasonable agreement with an “adjusted R
Niosomal formulation comprised of different concentrations of 
surfactant showed significant variation in vesicle size.
and maximum vesicle size for developed nitrendipine loaded 
niosomal formulations were found 230.4 nm for NIF 8 and 566.2 nm 
for NIF 4, respectively (table 2). The quadratic equation for response 
Y1 to represent the relationship is shown as:  
 Y1(Vesicle size) = 345.42 − 3.56A + 11.40B − 151.96
− 1.18BC + 10.74A2 + 25.26B
The negative value of A and C in the equation represents vesicle 
size decreases as the concentration of span 60 and temperature is 
increased, whereas positive coefficients were observed with B 
such that vesicle size increases at a high concentration of 
cholesterol. The possible reason behind this could be increased 
hydrophobicity of the bilayer membrane, which results in an 
increase in vesicle size. At a high concentration of span 60, the 
cholesterol content and non-ionic surfactant are in close packing
which results in the formation of micellar structure hence, size is 
reduced [27, 35]. Results obtained by this model for vesicle size 
  
Fig. 2: Contour plots for vesicle size (a
independent variables (A= Span 60; B= Cholestero
Sharma et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 
 
-
is large could 
-squared of 0.9531. 
 The minimum 
C + 38.37AB + 25.40AC
2 + 28.79C2 
, 
represented by 3-dimensional response surface plots fig. 1 (a
and contour plots are shown in fig. 2 (a
Response 2 (Y2): effect of 
entrapment efficiency 
The entrapment efficiency is a percentage fraction of the entire drug 
engaged within the vesicles. Developed formulations were found in 
the range of 80.04% to 95.97%
The model F-value of 4.860 indicated that 
with only 2.45 % chance that “
due to noise. The value of “Probe>F” less than 0.0500 implies model 
term is significant and in this case C, C
The “Lack of Fit F-value” of 0.270
significant relative to the pure error with only 
this large could occur due to noise. 
“adjusted R-squared” were found to be 0.





Form the above equation it was observed that independent variable
(span 60) and C (Temperature) have 
entrapment efficiency while B (cholesterol) shows negative relation with 
entrapment efficiency. The non-
leakage of drug from vesicles and results in increased entrapment of 
drug within the vesicle. The increased content of cholesterol ma
compete with the drug to entrap with
drug and shows negative relation
this model for entrapment efficiency represented by 3
response plots fig. 1 (d-f) and contour plots as given in 
-c), entrapment efficiency (d-f) and polydispersity index (g
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Response 3 (Y3): effect of the independent variable on 
polydispersity index 
The degree of homogeneity of the size distribution of particle is 
described by the polydispersity index. All niosomal formulations 
shown polydispersity index with narrow size distribution and 
observed within the range of 0.227 to 0.478 (table 2). The model F-
value of 812.11 implies that the model is significant with only a 0.01 
% chance that “model F-value” this large could occur due to noise. 
The value of “Probe>F” less than 0.0500 implies model term is 
significant in this case A, B, C, AB, AC, BC, B2, C2were significant 
model terms. The “Lack of Fit F-value” of 0.323 shows the lack of Fit 
was not significant relative to the pure error with only an 80.94% 
chance that this large could occur due to noise. The “predicted R-
squared” and “adjusted R-squared” were found to be 0.995 and 
0.997 respectively and following quadratic equation was obtained- 
 Y3(Polydispersity index) = 0.3824 + 0.009125A + 0.003375B − 0.11C +
0.01775AB + 0.0065AC + 0.0095BC −  0.002325A2 + 0.01267B2 −
0.031575C2  
The results pointed, with increasing concentration of independent 
variable (Factor A) polydispersity index increased. The independent 
variable (Factor B) was found to have a positive effect initially and 
reduces with further increase. The polydispersity index was 
observed negative with the independent variable (Factor C) and 
reflecting improved homogeneity in niosomal formulation [50]. 
Results were examined by this model for the polydispersity index 
represented by 3-dimensional response plots fig. 1 (g-i) and contour 
plots given in fig. 2 (g-i). 
Optimization of nitrendipine loaded niosomes  
The point prediction method of design expert software was 
employed to optimize the developed nitrendipine loaded niosomal 
formulations. The optimized niosomal formulation was selected 
based on the criteria of attaining maximum entrapment efficiency 
with minimum globule size and polydispersity index. Hence, to 
verify the model optimum checkpoint formulations were prepared 
and their evolutions were found within the limits. Upon “trading off” 
various value of response variables, evaluation of feasibility search 
and exhausted grid search, formulation with span 60 (4.52 mmol), 
cholesterol (1.85 mmol), and temperature (60 °C) was found to full 
fill the requisites for an optimum formulation. The optimized value 
for each dependent variable Y1, Y2, and Y3 were found to be 
226.1±4.36 nm, 95.34±3.18 %, and 0.282±0.012 respectively. The 
selected optimized formulation was converted into the gel and 
evaluated for further transdermal efficiency. 
Morphology of nitrendipine loaded niosomes 
To assess particle size distribution (fig. 3a) and morphological 
characteristics (fig. 3b) of niosomes, transmission electron 
microscopy was performed. 
 
 
Fig. 3: (a) Vesicle size distribution (b) Transmission electron microscopy of nitrendipine optimized formulation 
 
The spheres like the shape of vesicles with sharp boundaries were 
obtained. In contrast, the core and outline of nitrendipine loaded 
niosomal formulation were well identified and displayed sealed 
vesicular structure [27]. 
Characterization of optimized niosomal gel 
The prepared gel was observed clear and smooth. No aggregate or 
clumps observed in all prepared formulation and exhibit 
homogenous nature. The pH and drug content for optimized 
niosomal gel was found to be 6.26±0.208 and 99.91±0.288 
respectively. The result for viscosity (11.87±1.77 PaS) of optimized 
formulation was found satisfactory for transdermal application. 
In vitro release profile of nitrendipine niosomal gel  
Loaded drug from the niosomal vesicular system was carried into 
the medium by diffusion through cellophane membrane. The results 
pointed out that, drug encapsulated gel formulations show rapid 
release initially and then sustained release in the late hours of study. 
 
Table 3: Detail on the in vitro release data to the different mathematical model for an optimized gel formulation 
Model Equation R2 
Zero-order  Q0 − Qt =  K0t  0.765 
First-order Log C = Log C0 − Kt/2.303 0.824 




= Ktn  0.929  
Best Fit Mode Higuchi Model  
  
The in vitro release data thus obtained for optimized niosomal gel 
was fitted into different mathematical release models. The highest 
value of the correlation coefficient (R2) would be selected best-fit 
model for release. The results obtained are listed in table 3 and the 
advocated best-fit model for optimized gel was Higuchi matrix 
model where it showed the highest R2value of 0.945. Results confirm 
the sustained delivery of the drug from niosome for a prolonged 
period with a diffusion control pattern and found in the agreement 
with results obtained and reported by previous research studies 
[24]. Thus, considering the above outcome, the 
gel was selected for ex-vivo permeation studies.
Ex-vivo permeation study 
The ex-vivo permeation study of niosomal dispersion, 
niosomal gel, and the plain gel was examined through 
rat skin. The steady-state transdermal flux was determined by 
plotting the graph between the cumulative 
permeated versus time and compared. The transdermal flux for 
niosomal dispersion, optimized niosomal gel and 
the end of 24 h was found to be 141.40±2.31, 127.6
 
Fig. 4: Percent drug diffused through rat skin for nitrendipine plain gel, niosomal dispersion and optimized niosomal gel
Confocal laser scanning microscopy (CLSM)  
The Rhodamine red (RR) dye was entrapped to investigate 
penetration behavior of optimized niosomal gel
stratum corneum, as it is a rate-limiting step in transdermal delivery 
of the drug. CLSM results demonstrate niosomal formulation wa
adequately and evenly distributed through different
 
Fig. 5: Confocal laser scanning microscopy images showing distribution and deep
treated with (A) Niosomal gel (B) Rhodamine red solution
Table 4: Detail on the skin irritation 
Untreated control 
Rat No Erythemaa Edema
1 0 0 
2 0 0 
3 0 0 
4 0 0 
5 0 0 
6 0 0 
Averag 0 0 
mean±SD; n=6, aErythema scale: 0, none; 1, sligh
severely irritant 5 to 8 
Sharma et al. 





amounts of drug 
plain drug gel at 
0±3.17 and 
88.73±1.67 µg/cm2 hrespectively
increased flux value for niosomal gel 
plain drug gel. The above outcome
permeation enhancer in niosomal formulation
reduced crystallinity of the lipid bilayer of 
permeation through rat skin. Th
niosomal formulation (P>0.05)
lower transdermal flux than comparing
which may be due to the high v
research findings are supported with 
literature whereby gel formulation was favored over niosomal 
dispersion due to its suitability on the skin surface
 
the 
 formulation through 
s 
 layers of skin 
with high fluorescence intensity
transdermal potential of nitrendipine
of the skin. The maximum depth
observed with optimized niosomal
rhodamine red solution through rat skin
results proved improved skin penetration potential of 
niosomal formulations for transdermal drug delivery
 penetration of Rhodamine red through rat skin when 
 
 
scores after transdermal application of niosomal gel on Wistar rats
Niosomal dispersion treated Niosomal gel treated
b Erythemaa Edemab Erythema
2 1 1 
1 1 1 
1 1 1 
2 1 1 
0 1 1 
1 1 1 
1.16±0.68 1.00±0.0 1.00
t; 2, irritant; 2-5 and severely irritant 5 to 8, bEdema scale: 
181-189 
187 
 (fig. 4). The results demonstrated 
(P<0.05) than compared to 
 justifying the fact of span 60 as a 
, which resulted in 
the skin, thus improve 
ere was no significant difference in 
. It was found that niosomal gel has a 
 to niosomal dispersion, 
iscosity of the gel formulation. These 
a previous study reported in 
 [26]. 
 
 (mean±SD; n = 3) 
. Fig. 5 (A, B) displays the 
 niosomal gel in deeper levels 
 after a transdermal application was 
 gel formulation than compare to 
. The outcome of the above 
optimized 












0, none; 1, slight; 2, irritant; 2-5 and 
Results confirmed no significant changes in rat skin
niosomal dispersion and niosomal gel than compared 
control skin (fig. 6 A-C) and shows defined dermal, epidermal
Fig. 6: Histopathological cross-sections of rat skin stained with haematoxylin and eosin (A) untreated 
Stability study 
Stability studies were carried out for optimized 
following ICH guidelines. The optimized niosomal 
was kept under the stressed condition of temperature and humidity 
and evaluated for clarity, pH, and drug content.
significant changes observed in the formulation and
stable in both stressed conditions. 
CONCLUSION 
In the present investigation, nitrendipine loaded niosomal gel wa
successfully prepared by the thin-film hydration method.
formulation was optimized by box-behnken 
achieve desired properties using different ratio
cholesterol, whereas the addition of carbopol 934P found to produce 
niosomal gel with suitable viscosity for transdermal application
optimized formulation showed satisfactory vesicle
index, and enhanced entrapment efficiency. Further, confocal laser 
scanning microscopy confirmed the deep penetration of 
through rat skin. In vivo histopathological investigation justifies 
nitrendipine niosomal gel system to be a safe, effective
surrogate carrier for transdermal delivery. Niosomal gel was found 
stable in both elevated conditions of temperature and relative 
humidity. The present study reveals niosomal gel 
carrier for transdermal delivery of nitrendipine. 
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